Pitchford is managing director of healthcare investments at Imperial Innovations Group, a UK-listed venture capital firm that primarily supports spin-outs from British universities after its own spin out from Imperial College London.

UK-based biotech company PolyTherics has appointed experienced venture investors Anker Lundemose and Nigel Pitchford to its board.

Pitchford is managing director of healthcare investments at Imperial Innovations Group, a UK-listed venture capital firm that primarily supports spin-outs from British universities after its own spin out from Imperial College London.

Lundemose is co-founder of several companies including Symphogen, Santaris and Prosidion, a UK subsidiary of OSI Pharmaceuticals where he had been a managing director of OSI’s corporate venturing unit. 

PolyTherics has raised £7.45m ($10m) and is backed by Imperial Innovations, Proven Health VCT, The Capital Fund (managed by YFM), and a number of high net worth individuals with funds managed by Longbow Capital.

PolyTherics’ last round raised £2.15m in September last year.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?